Industry
Life Sciences
As life science companies expand production capabilities in Australia, they rely on CBRE for their real estate services.
The Life Sciences industry is a major growth sector in Australia, contributing to growing occupier demand and rising commercial property investment activity. This aligns with global companies expanding their Australian production capabilities, including research and development, manufacturing and distribution.
Occupiers and investors trust CBRE for our in-depth knowledge of this highly regulated sector, spanning multiple categories and property types. The industry encapsulates, Biotechnology, Pharmaceutics, Food Science, Digital Health, and Complimentary Healthcare, amongst others.
We specialise in providing real estate investors with acquisition, disposition and debt and equity recapitalisation strategies across the continuum of care, including life sciences, specialised and general acute care, long-term acute care, and other post-acute care operations.
Our Specialised Services
- Acquisition and disposal of assets
- Sale and leaseback structuring
- Assisting health systems, investors and developers in the monetisation of their owned real estate
- Structuring equity (co-GP, preferred equity, and LP capital) for new development projects
- Providing innovative financing solutions through solid lender connections
- Preparation of assets for sale including asset registers, technical due diligence (TDD) assessments, financial modelling and lease due diligence
Core Capabilities
Viewpoint
Life Sciences: Mapping Occupiers across major Australian Cities
Understanding the Life Sciences Landscape in Australia
We mapped ~130 Life Sciences organisations across Brisbane, Melbourne, Perth and Sydney, with a focus on R&D, contract research/trials and medical manufacturing.
Related Insights
-
Article | Intelligent Investment
Alternatives: The not-so-alternative sectors driving economic growth
April 11, 2025
An expert guide to maintaining a healthy and balanced property portfolio through Alternatives.
-
Article | Intelligent Investment
Alternative assets: What you need to know about this $100 billion investment market
September 5, 2024
The rise of the alternative asset class is here, and it comes with a substantial investment market worth $100 billion in Australia.
While this may pique the interest of many inves -
Article | Intelligent Investment
Why US investors allocated $1.43 billion into this Australian industry
August 21, 2024
Significant investment injection has transformed Australia’s Life Sciences industry into a major growth sector.
Leadership
Chris O'Brien
Executive Director, Industrial & Logistics, Capital Markets, APAC
Sandro Peluso
Director, Healthcare & Social Infrastructure, Capital Markets, Australia
2025 Australian Healthcare & Childcare Reports
Explore Australia's leading healthcare & childcare property investments.
